Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 8,380 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: serum sample Clear all
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

NCT04393454
View directory record Official record
Conditions
Metastatic dMMR Solid Cancer, Solid Tumor, Cancer, Metastatic Solid Tumor
Interventions
Sirolimus 2mg Tablet
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 28, 2026, 1:44 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT07318805
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions
PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Duarte, California • Grand Rapids, Michigan • Long Island City, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 28, 2026, 1:44 PM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

NCT03650894
View directory record Official record
Conditions
Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor
Interventions
Nivolumab, Ipilimumab, Bicalutamide
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 28, 2026, 1:44 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

NCT05593094
View directory record Official record
Conditions
Advanced Solid Tumors, HER2-positive Breast Cancer
Interventions
ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Cerritos, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 1:44 PM EDT
Recruiting Phase 2 Interventional

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

NCT07446322
View directory record Official record
Conditions
Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
Interventions
Bevacizumab, FOLFIRI, Pelareorep
Drug
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
19
States / cities
Homewood, Alabama • Beverly Hills, California • Encino, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 1:44 PM EDT
Completed Phase 1 Interventional

Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA

NCT01238237
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM), ANAPLASTIC ASTROCYTOMA (AOA), GBM, Anaplastic Astrocytoma
Interventions
Superselective Intraarterial Cerebral Infusion of Cetuximab
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 28, 2026, 1:44 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
109
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 28, 2026, 1:44 PM EDT
Completed Phase 2 Interventional

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

NCT00053196
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, G-CSF, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic cell transplantation, allopurinol
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
12
States / cities
La Jolla, California • Lewes, Delaware • Newark, Delaware + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 28, 2026, 1:44 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

NCT01450696
View directory record Official record
Conditions
Gastric Cancer
Interventions
Capecitabine, Cisplatin, Herceptin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • Whittier, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 28, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

NCT02096861
View directory record Official record
Conditions
Crohn's Disease
Interventions
CT-P13, Remicade
Biological
Lead sponsor
Celltrion
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 28, 2026, 1:44 PM EDT
Active, not recruiting Phase 2 Interventional

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

NCT06522386
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Pirtobrutinib, Rituximab, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 28, 2026, 1:44 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

NCT01549886
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Y-90-Zevalin, Moxtezafin Gadolinium, Rituximab
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Berkeley, California • Burbank, California • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 28, 2026, 1:44 PM EDT
Recruiting Phase 1 Interventional

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT05067283
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Calderasib, Pembrolizumab, carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Tampa, Florida • Grand Rapids, Michigan • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 1:44 PM EDT
Completed Phase 1 Interventional

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

NCT00405405
View directory record Official record
Conditions
Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma, Stage IV Head and Neck Cancer
Interventions
Cisplatin, Docetaxel, Bevacizumab, Erlotinib, Radiotherapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 28, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

NCT03829722
View directory record Official record
Conditions
Oropharynx Squamous Cell Carcinoma
Interventions
Nivolumab, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 28, 2026, 1:44 PM EDT
Completed No phase listed Observational

Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients

NCT01023451
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 28, 2026, 1:44 PM EDT
Terminated Phase 3 Interventional Results available

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

NCT01662102
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Zevalin, Rituximab
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Sun City, Arizona • Athens, Georgia • Niles, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 28, 2026, 1:44 PM EDT
Terminated Not applicable Interventional

Choice of Modality of Follow up for Medication Abortion

NCT04056637
View directory record Official record
Conditions
Abortion in First Trimester
Interventions
Choice of follow-up option, Multi-level pregnancy test
Other · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 28, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

Multicenter Uveitis Steroid Treatment (MUST) Trial

NCT00132691
View directory record Official record
Conditions
Uveitis
Interventions
fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
13 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 28, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

Trial to Optimize Mineral Outcomes in Dialysis Patients

NCT01100723
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Cinacalcet, active vitamin D analogue
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 28, 2026, 1:44 PM EDT
Completed Phase 2 Interventional

Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies

NCT00143559
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
Interventions
Systematic chemotherapy and antibodies, Allogeneic stem cell transplantation, Miltenyi CliniMACS
Drug · Procedure · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Oct 28, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Heartland Osteoporosis Prevention Study

NCT02186600
View directory record Official record
Conditions
Osteopenia
Interventions
Calcium Carbonate, Vitamin D3, Risedronate, Bone-loading exercises
Drug · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 28, 2026, 1:44 PM EDT
Completed Phase 2 Interventional

Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy

NCT01472510
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Vitreo-Retinal Associates, PC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 28, 2026, 1:44 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

NCT03505320
View directory record Official record
Conditions
Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin, Pharmacokinetics of Fluorouracil Bolus (5-FU)
Interventions
zolbetuximab, oxaliplatin, leucovorin, fluorouracil, Pembrolizumab, folinic acid, nivolumab, Docetaxel
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 28, 2026, 1:44 PM EDT